At the intersection of technology and biology, a revolution is quietly underway. Neuralink, the brain-computer interface company founded by Elon Musk, is working to directly connect the human brain to computers through implanted devices.
With the recent breakthrough achieved by Neuralink in clinical trials, brain-machine interface technology has transitioned from science fiction to reality.
01 Technological Leap: From Laboratory to Patient Life
In 2025, Neuralink made remarkable progress in the field of brain-machine interfaces, with several clinical trials demonstrating life-changing results.
The first patient to receive the N1 implant, Noland Arbaugh, has been able to control digital devices with his thoughts, play video games, and even re-establish communication with the outside world.
For patients with spinal cord injuries and amyotrophic lateral sclerosis (ALS), this technology is not just a convenience, but a reconstruction of life.
The core of Neuralink’s technology lies in the precise design of its N1 implant. This device features 1,000 ultra-thin electrodes that can capture and interpret neural signals with high resolution.
Compared to traditional brain-machine interfaces, it has significantly improved signal sensitivity and device endurance, providing a foundation for complex brain-machine interactions.
Even more astonishing is that the Neuralink system has achieved a completely wireless connection, allowing patients to no longer be exposed to cumbersome external wires, greatly enhancing the practicality of the device and the quality of life.
02 Visual Revolution: Blindsight Project Breakthrough
Neuralink has also made significant progress in the field of vision restoration. The company’s "Blindsight" project has received the FDA’s designation as a "breakthrough device."
This project aims to restore partial visual function for blind patients by directly stimulating the visual cortex.
Although Neuralink’s specific clinical data in this field has not been fully disclosed, the concept of brain-machine interfaces for visual restoration has been validated.
The PRIMA retinal implant developed by its competitor Science Corporation (founded by Neuralink’s first president Max Hodak) has successfully helped patients blinded by macular degeneration regain the ability to read text and do crossword puzzles.
The research results of Science Corporation were published in the prestigious New England Journal of Medicine, showing that over 80% of participants experienced "clinically significant visual improvement" after 12 months. This success provides strong scientific endorsement for Neuralink’s Blindsight project.
03 Regulatory Green Light: The Essential Path to the Market
As an innovative medical device, brain-computer interfaces have attracted significant attention regarding their regulatory pathways. According to the classification by the U.S. FDA, brain-computer interface products are subject to different regulatory pathways based on their mode of invasiveness and functional risks.
Non-invasive products mostly fall under medium risk and are declared through the 510K pathway; while invasive products carry higher risks and must go through the 510K or the more stringent PMA (Pre-Market Approval) pathway.
The FDA has also established the "Breakthrough Devices Program" for innovative devices, with companies like Neuralink and Synchron receiving this certification.
This plan is similar to the approval policies for innovative medical devices by China’s NMPA, which can help companies gain more opportunities to communicate with FDA experts during the listing process, accelerating the approval process.
Currently, the number of brain-computer interface products approved by the FDA is limited, and the "IpsiHand Upper Limb Rehabilitation System" produced by Neurolutions became the first non-invasive brain-computer interface robot approved for rehabilitation in April 2021.
04 Market Outlook: The Commercial Potential of Brain-Computer Interfaces
The global brain-computer interface market is at a critical turning point of "technological breakthroughs, clinical validation, and commercial implementation."
According to McKinsey’s estimates, by 2030, the global market size of brain-computer interfaces in the medical application field is expected to reach 40 billion dollars, and by 2040, this figure is expected to exceed 145 billion dollars.
This growth is not only driven by the demand for medical rehabilitation but also stems from potential applications in the consumer technology sector.
The analysis report from Founder Securities points out that brain-computer interfaces are regarded as a revolutionary underlying technology for the next generation of human-computer interaction, with medical rehabilitation being its first breakthrough application.
In the long term, this technology is expected to reshape the ecosystem of multiple industries such as education, entertainment, and military.
Neuralink, with its technological advantages, is expected to occupy an important share in this rapidly growing market. The company’s wireless, high-resolution interface technology is not only applicable to medical rehabilitation but also shows potential for applications in consumer fields such as gaming, virtual reality, and cognitive enhancement.
05 Investment Perspective: Opportunities and Challenges Coexist
From an investment perspective, Neuralink represents a high-risk, high-reward opportunity. The global brain-computer interface market is expected to continue expanding at a compound annual growth rate of 25% until 2030.
Against this backdrop, if Neuralink can maintain its technological edge, it is likely to capture a significant market share.
However, investors must also be clearly aware of the challenges faced in the field of brain-computer interfaces. Technical reliability, long-term safety, and ethical issues are all obstacles that companies need to overcome.
For example, Neuralink has reported technical issues with the contraction of fine wire electrodes in devices, which require ongoing research and development to address.
In terms of regulation, although the FDA has provided initial guidelines for brain-computer interface devices, including non-clinical and clinical considerations, the regulatory framework may still change as technology develops, which is a risk factor that investors need to pay attention to.
06 Neuralink Token: The Correlation Dynamics of the Crypto Market
It is worth noting that tokens containing "Neuralink" in their name have appeared in the crypto market. As of data on October 22, a token named NEURALINK has a price of $0.000088999, a market cap of approximately $88,000, and has increased by 286.99% in the past 24 hours.
It should be made clear that these tokens have no official association with Neuralink itself; they are merely cryptocurrency assets leveraging a hot concept.
For investors trading on the Gate exchange, it is essential to carefully assess the substance of the tokens and refer to the latest real-time data from the platform as of October 22.
Future Outlook
The technological breakthrough of brain-computer interfaces is no longer limited to laboratories. Guotai Junan Securities points out that the global brain-computer interface market is at a critical turning point of "technological breakthroughs, clinical validation, and commercial implementation."
With the continuous maturation of technology and the expansion of application scenarios, the brain-machine interface technology represented by Neuralink is expected to gradually expand from the medical rehabilitation field to a broader consumer technology market in the next decade, truly achieving a seamless connection between humans and machines.
This journey has just begun.
